Description
Dapagliflozin 10 mg is a once-daily SGLT2 inhibitor effective for lowering blood sugar in type 2 diabetes while offering cardiovascular and renal benefits, including heart failure risk reduction and slowed CKD progression. It encourages urinary glucose loss, aiding in moderate weight loss and blood pressure reduction.
Mechanism of Action:
Dapagliflozin blocks the SGLT2 transporter in kidney proximal tubules, reducing glucose reabsorption and promoting its excretion in urine. This leads to lower blood glucose levels, mild weight loss, and a decrease in blood pressure due to osmotic diuresis.
Uses:
- Type 2 diabetes mellitus (T2DM): to improve glycemic control as mono‑ or add‑on therapy
- Heart failure: reduce risk of hospitalization and death in adults with heart failure, with or without diabetes
- Chronic kidney disease (CKD): slow progression in adults with or without diabetes
